Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317503546> ?p ?o ?g. }
- W4317503546 abstract "Abstract Background Historically, high hepatocellular carcinoma (HCC)–related mortality has been, in part, due to lack of effective therapies; however, several systemic therapies have been recently approved for HCC treatment, including regorafenib and ramucirumab. These two treatments utilize different routes of administration (four daily tablets and biweekly intravenous infusions, respectively) and have different risks of adverse events (AEs). However, we lack data on patient preferences in balancing the route of administration and risk of AEs in patients with HCC. We aimed to determine patient preferences and trade-offs for second-line treatment in patients with HCC. Methods Patients with advanced or metastatic HCC were recruited through their physicians for this study. Patient preferences were assessed by using a modified threshold technique (TT) design in which respondents were asked two direct-elicitation questions before (assuming same safety and efficacy and only varying mode of administration) and after (incorporating the safety profiles of ramucirumab and regorafenib) the TT series on seven risks of clinically relevant AEs. Results In total, of the 157 patients recruited by their physicians, 150 were eligible and consented to participate. In the first elicitation question (assuming risk and efficacy were equivalent), 61.3% of patients preferred daily tablets. However, 76.7% of patients preferred the biweekly infusion when the safety profiles of the two available second-line therapies were included. The TT analysis confirmed that preferences for oral administration were not strong enough to balance out the risk of AEs that differentiate the two therapies. Discussion We found that when patients were asked to choose between a daily, oral medication and a biweekly IV medication for HCC, they were more likely to choose a daily, oral medication if efficacy and safety profiles were the same. However, when risks of AEs representing the safety profiles of two currently available second-line treatments were introduced in a second direct-elicitation question, respondents often selected an IV administration with a safety profile similar to ramucirumab, rather than oral tablets with a safety profile similar to regorafenib. Our findings indicate that the risk profile of a second-line treatment for HCC may be more important than the mode of administration to patients." @default.
- W4317503546 created "2023-01-20" @default.
- W4317503546 creator A5005128372 @default.
- W4317503546 creator A5010311977 @default.
- W4317503546 creator A5016304590 @default.
- W4317503546 creator A5040663276 @default.
- W4317503546 creator A5046621434 @default.
- W4317503546 creator A5048405172 @default.
- W4317503546 creator A5049458198 @default.
- W4317503546 creator A5064121924 @default.
- W4317503546 date "2023-01-19" @default.
- W4317503546 modified "2023-10-14" @default.
- W4317503546 title "Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study" @default.
- W4317503546 cites W1828082159 @default.
- W4317503546 cites W1905936368 @default.
- W4317503546 cites W1971837077 @default.
- W4317503546 cites W1973742157 @default.
- W4317503546 cites W1987629986 @default.
- W4317503546 cites W2052456753 @default.
- W4317503546 cites W2056568077 @default.
- W4317503546 cites W2094438867 @default.
- W4317503546 cites W2113354881 @default.
- W4317503546 cites W2115020535 @default.
- W4317503546 cites W2148417448 @default.
- W4317503546 cites W2509578420 @default.
- W4317503546 cites W2529646902 @default.
- W4317503546 cites W2530417471 @default.
- W4317503546 cites W2560499218 @default.
- W4317503546 cites W2774659630 @default.
- W4317503546 cites W2809889937 @default.
- W4317503546 cites W2943780807 @default.
- W4317503546 cites W2945730831 @default.
- W4317503546 cites W2974120070 @default.
- W4317503546 cites W2979900859 @default.
- W4317503546 cites W2980679133 @default.
- W4317503546 cites W3007662375 @default.
- W4317503546 cites W3008192517 @default.
- W4317503546 cites W3024467897 @default.
- W4317503546 cites W3028482830 @default.
- W4317503546 cites W3045343997 @default.
- W4317503546 cites W3127782710 @default.
- W4317503546 cites W3128646645 @default.
- W4317503546 cites W3184564649 @default.
- W4317503546 cites W3201209775 @default.
- W4317503546 cites W4283772058 @default.
- W4317503546 doi "https://doi.org/10.1186/s12885-022-10388-8" @default.
- W4317503546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36658529" @default.
- W4317503546 hasPublicationYear "2023" @default.
- W4317503546 type Work @default.
- W4317503546 citedByCount "0" @default.
- W4317503546 crossrefType "journal-article" @default.
- W4317503546 hasAuthorship W4317503546A5005128372 @default.
- W4317503546 hasAuthorship W4317503546A5010311977 @default.
- W4317503546 hasAuthorship W4317503546A5016304590 @default.
- W4317503546 hasAuthorship W4317503546A5040663276 @default.
- W4317503546 hasAuthorship W4317503546A5046621434 @default.
- W4317503546 hasAuthorship W4317503546A5048405172 @default.
- W4317503546 hasAuthorship W4317503546A5049458198 @default.
- W4317503546 hasAuthorship W4317503546A5064121924 @default.
- W4317503546 hasBestOaLocation W43175035461 @default.
- W4317503546 hasConcept C121608353 @default.
- W4317503546 hasConcept C126322002 @default.
- W4317503546 hasConcept C143998085 @default.
- W4317503546 hasConcept C197934379 @default.
- W4317503546 hasConcept C2776248978 @default.
- W4317503546 hasConcept C2778019345 @default.
- W4317503546 hasConcept C2779551604 @default.
- W4317503546 hasConcept C2780140570 @default.
- W4317503546 hasConcept C526805850 @default.
- W4317503546 hasConcept C71924100 @default.
- W4317503546 hasConceptScore W4317503546C121608353 @default.
- W4317503546 hasConceptScore W4317503546C126322002 @default.
- W4317503546 hasConceptScore W4317503546C143998085 @default.
- W4317503546 hasConceptScore W4317503546C197934379 @default.
- W4317503546 hasConceptScore W4317503546C2776248978 @default.
- W4317503546 hasConceptScore W4317503546C2778019345 @default.
- W4317503546 hasConceptScore W4317503546C2779551604 @default.
- W4317503546 hasConceptScore W4317503546C2780140570 @default.
- W4317503546 hasConceptScore W4317503546C526805850 @default.
- W4317503546 hasConceptScore W4317503546C71924100 @default.
- W4317503546 hasFunder F4320307758 @default.
- W4317503546 hasIssue "1" @default.
- W4317503546 hasLocation W43175035461 @default.
- W4317503546 hasLocation W43175035462 @default.
- W4317503546 hasLocation W43175035463 @default.
- W4317503546 hasOpenAccess W4317503546 @default.
- W4317503546 hasPrimaryLocation W43175035461 @default.
- W4317503546 hasRelatedWork W2131794175 @default.
- W4317503546 hasRelatedWork W2518932857 @default.
- W4317503546 hasRelatedWork W2886768770 @default.
- W4317503546 hasRelatedWork W2942632018 @default.
- W4317503546 hasRelatedWork W3040708616 @default.
- W4317503546 hasRelatedWork W3084251940 @default.
- W4317503546 hasRelatedWork W3138551344 @default.
- W4317503546 hasRelatedWork W3186827829 @default.
- W4317503546 hasRelatedWork W4385898854 @default.
- W4317503546 hasRelatedWork W58757199 @default.
- W4317503546 hasVolume "23" @default.
- W4317503546 isParatext "false" @default.
- W4317503546 isRetracted "false" @default.